newsfilter
← Latest News
Business Wire·

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

  • AN2 Therapeutics announced a poster presentation regarding its planned Phase 2 trial of epetraborole for polycythemia vera patients.
  • The poster, titled "Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV," will be presented at the 18th International Congress on Myeloproliferative Neoplasms.
  • The presentation is scheduled for Thursday, October 29, 2026, from 5:45-7:15pm ET, with poster number 148.
  • The congress will take place October 29-30, 2026, in Brooklyn, New York.
  • AN2 Therapeutics is a clinical stage biopharmaceutical company utilizing a boron chemistry platform to develop small molecule therapeutics.
  • The company expects three Phase 2 studies to be active in 2026, including programs in hematologic diseases, infectious diseases, & oncology.